Evidence map›Paper›PMID 29895587›Full record

ArticleJournal of the American Heart Association2018

Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Adam D DeVore, Xiaojuan Mi, Laine Thomas, Puza P Sharma, Nancy M Albert, Javed Butler, Adrian F Hernandez, J Herbert Patterson, John A Spertus, Fredonia B Williams and 3 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. With great power comes great… reliability.European journal of heart failure · 2020
    Article
  15. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.Journal of the American College of Cardiology · 2019
    Observational
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Adam D DeVoreDuke Clinical Research Institute, Durham, NC adam.devore@duke.edu.
Xiaojuan MiDuke Clinical Research Institute, Durham, NC.
Laine ThomasDuke Clinical Research Institute, Durham, NC.
Puza P SharmaNovartis Pharmaceuticals Corporation, East Hanover, NJ.
Nancy M AlbertCleveland Clinic, Cleveland, OH.
Javed ButlerUniversity of Mississippi Medical Center, Jackson, MS.
Adrian F HernandezDuke Clinical Research Institute, Durham, NC.
J Herbert PattersonEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.
John A SpertusSaint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Kansas City, MO.
Fredonia B WilliamsMended Hearts, Huntsville, AL.
Carol I DuffyNovartis Pharmaceuticals Corporation, East Hanover, NJ.
Kevin McCagueNovartis Pharmaceuticals Corporation, East Hanover, NJ.
Gregg C FonarowAhmanson-UCLA Cardiomyopathy Center Ronald Reagan UCLA Medical Center, Los Angeles, CA.
Tris Pharma (United States) · USClinical Research Institute · USDuke University · USButler University · USCleveland Clinic · USRonald Reagan UCLA Medical Center · USSaint Luke's Hospital · USUniversity of North Carolina at Chapel Hill · USWilliams (United States) · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2016 to 2025
$38.2M
NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

backgroundThe US Food and Drug Administration approved sacubitril/valsartan for patients with chronic heart failure (HF) with reduced ejection fraction in 2015 on the basis of the results of the PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor Neprilysin Inhibitor] With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. There are limited data assessing the generalizability of PARADIGM-HF trial participants to a broader population of patients with HF with reduced ejection fraction routinely encountered in outpatient clinical practice. METHODS AND

resultsWe compared the baseline characteristics of patients in the PARADIGM-HF trial with those in the CHAMP-HF (Change the Management of Patients With Heart Failure) study a large US outpatient registry of patients with HF with reduced ejection fraction. Patients in the PARADIGM-HF trial (n=8442) were similar to those in the CHAMP-HF registry (n=3497) in terms of age (mean, 64 versus 66 years), sex (22% versus 29% women), New York Heart Association class III to IV (25% versus 32%), systolic blood pressure (mean, 121 versus 121 mm Hg), left ventricular ejection fraction (mean, 29% versus 29%), and other key baseline characteristics. The median (25th-75

conclusionsThese data suggest participants randomized in the PARADIGM-HF trial have similar baseline characteristics to those encountered in routine outpatient clinical practice, but there is a substantial lag in the adoption of sacubitril/valsartan for patients with chronic HF with reduced ejection fraction.

Indexed as

Patient SelectionAgedAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsFemaleHeart FailureHumansMaleMiddle AgedNeprilysinObservational Studies as TopicProtease InhibitorsRandomized Controlled Trials as TopicRecovery of FunctionAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsNeprilysinProtease Inhibitorssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanangiotensin receptor neprilysin inhibitorquality improvementregistrysacubitril/valsartan

Identifiers

PMID29895587
PMCPMC6220559
OpenAlexW2807760375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.